Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
B/F/TAF versus dolutegravir + emtricitabine/tenofovir disoproxil fumarate in treatment-naive adults with HIV-1 and hepatitis B coinfection
2018-000926-79Phase 3Completed
- Sponsor
- Gilead Sciences
- Start
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of bictegravir, emtricitabine, tenofovir alafenamide, dolutegravir and tenofovir disoproxil fumarate in Human immunodeficiency virus infection type 1 and hepatitis B (HBV) (2 arms), sponsored by Gilead Sciences. Primary endpoint: Proportion of subjects with HIV-1 RNA < 50 copies/mL at Week 48. Started Jun 2018; status: completed.
02
Drugs
bictegraviremtricitabinetenofovir alafenamidedolutegravirtenofovir disoproxil fumarate
03
Conditions
Human immunodeficiency virus infection type 1hepatitis B (HBV)
Beyond the preview
Go deeper on 2018-000926-79.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000926-79.